SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview as part of the RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium, which is scheduled to take place virtually on Friday, October 7, 2022. Details of the presentation appear below:
Date: Friday, October 7, 2022
Time: 11:00am ET / 8:00am PT
Webcast Link: https://www.veracast.com/webcasts/rbc/lung2022/4X3iHP.cfm
To attend aTyr’s company presentation, register at the link above. To attend the KOL sessions, investors may contact their RBC sales representative to register. Following the event, a replay of the aTyr company presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com for at least 90 days.
aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com. Director, Investor Relations and Corporate Communications